Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of BMS-986278 in Hepatic Impairment
NCT06425198Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of admilparant in idiopathic pulmonary fibrosis (IPF) and pulmonary fibrosis (PF) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed concentration, Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration and 1 more. Started Jun 2024; status: completed.
02
Drugs
admilparant
03
Conditions
idiopathic pulmonary fibrosis (IPF)pulmonary fibrosis (PF)
Beyond the preview
Go deeper on NCT06425198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06425198.